Sood, Ashwani

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Sathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 210

225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks.

Vatsa, R., Sood, A., Vadi, S. K., Das, C. K., Kaur, K., Parmar, M., & Mittal, B. R. (2020) · Clinical Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 23

Alpha Before Beta: Exceptional Response to First-Line 225Ac-DOTATATE in a Patient of Metastatic Neuroendocrine Tumor With Extensive Skeletal Involvement.

Satapathy, S., Sood, A., Das, C. K., Kavanal, A. J., & Mittal, B. R. (2022) · Clinical Nuclear Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 14